QCLS
Q/C TECHNOLOGIES, INC.
Key Financials
Revenue
$1.6M
↓ 5.3%
Gross Profit
$478747
↑ 276.1%
Operating Income
$-9847357
↑ 3.2%
Net Income
$-11627122
↑ 50.2%
EPS (Diluted)
$-8.66
↑ 22.3%
Cash & Equivalents
$986996.00
↑ 470.0%
Shareholders' Equity
$21.8M
↑ 122.2%
Total Liabilities
$16.4M
↑ 145.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/15/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 10-K/A | 4/29/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 10-K | 4/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | QCLS |
| Company Name | Q/C TECHNOLOGIES, INC. |
| CIK | 1321834 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 856-848-8698 |